Vrbanec D - Search Results

1

Telomerase activity in breast cancer patients: association with poor prognosis and more aggressive phenotype.

Kulić A, Plavetić ND, Gamulin S, Jakić-Razumović J, Vrbanec D, Sirotković-Skerlev M. Kulić A, et al. Among authors: vrbanec d. Med Oncol. 2016 Mar;33(3):23. doi: 10.1007/s12032-016-0736-x. Epub 2016 Jan 30. Med Oncol. 2016. PMID: 26833480

2

Significance of epidermal growth factor receptor expression in breast cancer.

Badovinac-Crnjevic T, Jakic-Razumovic J, Podolski P, Pleština S, Sarčević B, Munjas R, Vrbanec D. Badovinac-Crnjevic T, et al. Among authors: vrbanec d. Med Oncol. 2011 Dec;28 Suppl 1:S121-8. doi: 10.1007/s12032-010-9738-2. Epub 2010 Nov 23. Med Oncol. 2011. PMID: 21104342

3

Prognostic value of proliferation markers expression in breast cancer.

Dedić Plavetić N, Jakić-Razumović J, Kulić A, Vrbanec D. Dedić Plavetić N, et al. Among authors: vrbanec d. Med Oncol. 2013 Jun;30(2):523. doi: 10.1007/s12032-013-0523-x. Epub 2013 Mar 7. Med Oncol. 2013. PMID: 23468220

4

Prognostic value of ki-67 in breast carcinoma: tissue microarray method versus whole section analysis- potentials and pitfalls.

Dedić Plavetić N, Jakić-Razumović J, Kulić A, Sirotković-Skerlev M, Barić M, Vrbanec D. Dedić Plavetić N, et al. Among authors: vrbanec d. Pathol Oncol Res. 2015 Apr;21(2):315-24. doi: 10.1007/s12253-014-9823-5. Epub 2014 Aug 6. Pathol Oncol Res. 2015. PMID: 25096394 Free article.

5

Circulating Her-2/neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, Her-2/neu receptor coexpression.

Barić M, Kulić A, Sirotković-Skerlev M, Dedić Plavetić N, Vidović M, Horvatić-Herceg G, Vrbanec D. Barić M, et al. Among authors: vrbanec d. Pathol Oncol Res. 2015 Jul;21(3):589-95. doi: 10.1007/s12253-014-9859-6. Epub 2014 Nov 4. Pathol Oncol Res. 2015. PMID: 25367073 Free article.

6

Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years).

Sirotković-Skerlev M, Plavetić ND, Sedlić F, Kuna SK, Vrbanec D, Belev B, Pleština S, Kovač Z, Kulić A. Sirotković-Skerlev M, et al. Among authors: vrbanec d. Cancer Biomark. 2021;30(1):95-104. doi: 10.3233/CBM-201497. Cancer Biomark. 2021. PMID: 32986661

7

Expression of Toll-like receptor 4 and beta 1 integrin in breast cancer.

Petricevic B, Vrbanec D, Jakic-Razumovic J, Brcic I, Rabic D, Badovinac T, Ozimec E, Bali V. Petricevic B, et al. Among authors: vrbanec d. Med Oncol. 2012 Jun;29(2):486-94. doi: 10.1007/s12032-011-9885-0. Epub 2011 Mar 13. Med Oncol. 2012. PMID: 21400218

8

Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients.

Kulić A, Sirotković-Skerlev M, Jelisavac-Cosić S, Herceg D, Kovac Z, Vrbanec D. Kulić A, et al. Among authors: vrbanec d. Med Oncol. 2010 Sep;27(3):887-93. doi: 10.1007/s12032-009-9301-1. Epub 2009 Sep 11. Med Oncol. 2010. PMID: 19763913

9

Nm23 gene product expression in invasive breast cancer--immunohistochemical analysis and clinicopathological correlation.

Belev B, Alerić I, Vrbanec D, Petrovecki M, Unusic J, Jakić-Razumović J. Belev B, et al. Among authors: vrbanec d. Acta Oncol. 2002;41(4):355-61. doi: 10.1080/028418602760169406. Acta Oncol. 2002. PMID: 12234027

10

Prognostic value of different factors in breast carcinoma.

Hlupić L, Jakić-Razumović J, Bozikov J, Corić M, Belev B, Vrbanec D. Hlupić L, et al. Among authors: vrbanec d. Tumori. 2004 Jan-Feb;90(1):112-9. doi: 10.1177/030089160409000123. Tumori. 2004. PMID: 15143983

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

80 results

Search Page

Filters